Table 4 Radiogenic side effects at the end of RT under DIBH and 3 months or 1 year thereafter
Grade | Acute dermatitis (n = 43) | 3 months after RT (n = 43) | 12 months after RT (n = 35) | ||||
|---|---|---|---|---|---|---|---|
Pneumonitis | Dermatitis | Breast fibrosis | Pneumonitis | Dermatitis | Breast fibrosis | ||
(A) | |||||||
0 | 3 | 41 | 14 | 26 | 35 | 30 | 29 |
1 | 33 | 2 | 29 | 15 | 0 | 5 | 4 |
2 | 7 | 0 | 0 | 2 | 0 | 0 | 2 |
3 months after RT | p (ANOVA) | 12 months after RT | p (ANOVA) | ||||
|---|---|---|---|---|---|---|---|
n (%) | MLDC | n (%) | MLDC | ||||
(B) | |||||||
3DCRT + DIBH | visual score 0 | 6 (14.0) | 12.0 ± 38.4 | < 0.001 | 8 (22.9) | 37.3 ± 83.1 | 0.119 |
Visual score 1 | 20 (46.5) | 49.4 ± 41.4 | 15 (42.9) | 49.6 ± 30.6 | |||
Visual score 2 | 17 (39.5) | 126.4 ± 54.9 | 12 (34.2) | 95.7 ± 92.5 | |||
3DCRT + FB | visual score 0 | 7 (28.0) | 32.4 ± 32.6 | 0.035 | 6 (40.0) | 20.3 ± 53.5 | 0.522 |
Visual score 1 | 11 (44.0) | 43.1 ± 19.3 | 6 (40.0) | 33.5 ± 21.8 | |||
Visual score 2 | 7/25 (28.0) | 71.4 ± 32.1 | 3 (20.0) | 53.7 ± 37.8 | |||